Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl-Fredrik Burman

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Biopharmaceutical Statistics|November 21, 2007
Discussion of the paper "Adaptive dose-ranging designs"Carl-Fredrik Burman
Statistics in Medicine|March 10, 2010
The dual test: safeguarding p-value combination tests for adaptive designsCarl-Fredrik Burman, Vera Lisovskaja
Statistics in Medicine|May 28, 2019
Modestly weighted logrank testsDominic Magirr, Carl-Fredrik Burman
Biometrics|September 21, 2006
Are flexible designs sound?Carl-Fredrik Burman, Christian Sonesson
Biometrical Journal. Biometrische Zeitschrift|November 14, 2014
A decision theoretic approach to optimization of multiple testing proceduresVera Lisovskaja, Carl-Fredrik Burman
Statistics in Medicine|October 2, 2012
On the choice of doses for phase III clinical trialsVera Lisovskaja, Carl-Fredrik Burman
Journal of Biopharmaceutical Statistics|September 19, 2017
A decision theoretical modeling for Phase III investments and drug licensingFrank Miller, Carl-Fredrik Burman
JAMA Oncology|February 9, 2023
The MaxCombo Test Severely Violates the Type I Error RateDominic Magirr, Carl-Fredrik Burman
Pharmaceutical Statistics|December 14, 2011
Modelling and simulation in the pharmaceutical industry--some reflectionsCarl-Fredrik Burman, Stig Johan Wiklund
Pharmaceutical Statistics|May 18, 2021
Selection bias, investment decisions and treatment effect distributionsStig Johan Wiklund, Carl-Fredrik Burman
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Biopharmaceutical Statistics|November 21, 2007
Discussion of the paper "Adaptive dose-ranging designs"Carl-Fredrik Burman
Statistics in Medicine|March 10, 2010
The dual test: safeguarding p-value combination tests for adaptive designsCarl-Fredrik Burman, Vera Lisovskaja
Statistics in Medicine|May 28, 2019
Modestly weighted logrank testsDominic Magirr, Carl-Fredrik Burman
Biometrics|September 21, 2006
Are flexible designs sound?Carl-Fredrik Burman, Christian Sonesson
Biometrical Journal. Biometrische Zeitschrift|November 14, 2014
A decision theoretic approach to optimization of multiple testing proceduresVera Lisovskaja, Carl-Fredrik Burman
Statistics in Medicine|October 2, 2012
On the choice of doses for phase III clinical trialsVera Lisovskaja, Carl-Fredrik Burman
Journal of Biopharmaceutical Statistics|September 19, 2017
A decision theoretical modeling for Phase III investments and drug licensingFrank Miller, Carl-Fredrik Burman
JAMA Oncology|February 9, 2023
The MaxCombo Test Severely Violates the Type I Error RateDominic Magirr, Carl-Fredrik Burman
Pharmaceutical Statistics|December 14, 2011
Modelling and simulation in the pharmaceutical industry--some reflectionsCarl-Fredrik Burman, Stig Johan Wiklund
Pharmaceutical Statistics|May 18, 2021
Selection bias, investment decisions and treatment effect distributionsStig Johan Wiklund, Carl-Fredrik Burman
Pageof 3